ClinicalTrials.gg
CompletedNCT00754403Updated Jul 5, 2010

Efficacy of Pioglitazone and Fortamet Combination Therapy in Subjects With Type 2 Diabetes

A Phase 4 interventional study of Pioglitazone and metformin and Metformin in Diabetes Mellitus, sponsored by Takeda. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-07-05.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's title name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Takeda · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
312
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 — 7 open to participants now, 8 under way, 1 of them phase 3. Pioglitazone · Diabetes Mellitus, Type 2.

Enrollment
30th of 122
312 · median 103
Started
2005
with 10 others
Phase 4
57 of 122
4 open now
Registered
46th of 122
by date
Lead sponsor
27 of 122
Takeda

Among the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, this one is the 30th largest by enrollment, is one of 11 that started in 2005, is one of 57 in phase 4, and was the 46th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About pioglitazone

Pioglitazone: first FDA approval 1999 (ACTOS), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to determine the efficacy of pioglitazone and metformin combination therapy, once daily (QD), on glycosylated hemoglobin in adults with type 2 diabetes.

Read the detailed description

Pioglitazone (ACTOS®) is a member of a class of oral antidiabetic agents known as thiazolidinediones. The insulin-sensitizing actions of thiazolidinediones are at least partially mediated through the peroxisome proliferator-activated receptor gamma. These receptors are found primarily in adipocytes, vascular endothelial cells, monocytes, hepatocytes, and to a lesser extent myocytes.

Metformin was developed as an extended-release formulation of metformin hydrochloride and designed for once-a-day oral administration. Metformin is an antihyperglycemic agent, which improves glucose tolerance in patients with, type 2 diabetes, lowering both basal and postprandial plasma glucose.

On 15 July 1999, the FDA approved pioglitazone for use as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. Pioglitazone is indicated for monotherapy and for use in combination with sulfonylureas, metformin, or insulin when diet and exercise plus the single agent do not result in adequate glycemic control. On 26 November 2003, the FDA approved the combined use of pioglitazone with metformin.

This study is designed to evaluate the effect on glycemic control when pioglitazone and metformin are taken together. Individuals participating in this study will provide written informed consent and will be required to commit to a screening visit and approximately 5 additional visits at the study center. Study participation is anticipated to be about 31 weeks (or approximately 8 months). Multiple procedures will occur at each visit which may include fasting, blood collection, urine collection, physical examinations and electrocardiograms.

03

Conditions studied

  • Diabetes Mellitus

Keywords

  • Glucose Metabolism Disorder
  • Dysmetabolic Syndrome
  • Type II Diabetes
  • Diabetes Mellitus, Lipoatrophic
  • Dyslipidemia
  • Drug Therapy
04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 312 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females of who are sexually active must agree to use adequate , and can neither be pregnant nor lactating from Screening throughout the duration of the study
  • Diagnosed with type 2 diabetes and must have received appropriate counseling on lifestyle modification for type 2 diabetes including diet and exercise.
  • If taking metformin monotherapy or metformin and sulfonylurea combination therapy, has a glycosylated greater than or equal to 7.5% and less than or equal to 9.0% at screening and randomization.
  • If naïve or taking sulfonylurea monotherapy has an glycosylated hemoglobin greater than or equal to 8.5% and less than or equal to 10.0% at screening and greater than or equal to 7.5% and less than or equal to 9.0% at randomization.

Exclusion criteria

Exclusion Criteria

  • Has type 1 diabetes mellitus
  • Currently taking any thiazolidinedione or have taken any thiazolidinedione within 12 weeks prior to screening
  • Has congestive heart failure; has a triglyceride level greater than 500 mg per dL
  • Diastolic blood pressure greater than 100 mmHg or a systolic pressure greater than 160 mmHg
  • greater than or equal to 42 kg/m2 (weight /height2)
  • level greater than or equal to 2.5 times the , active liver disease, or jaundice.
  • Male subjects who have a serum creatinine level greater than or equal to 1.5 mg per dL; female subjects who have a serum creatinine level greater than or equal to 1.4 mg per dL at the screening visit and at randomization.
  • Currently using insulin or has used insulin 3 months prior to Screening
  • Acute or chronic metabolic acidosis, including diabetic ketoacidosis with or without coma.
  • Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:

    • Chronically used oral or parenteral (eg, prednisone, cortisone, hydrocortisone, dexamethasone)
    • Niacin greater than 200 mg per day, including niacin-containing products such as Advicor - 3 months prior to screening and during the study
    • Chronically used steroid-joint injections - 3 months prior to screening and during the study
    • Thiazolidinediones - 3 months prior to screening and during the study
    • Insulin - 3 months prior to screening
    • Other oral antidiabetic medications (eg, nateglinide [Starlix], acarbose [Precose]) with the exception of sulfonylurea - 3 months prior to screening and during the study
    • Metformin - Fortamet Stabilization and during the study
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
312 participants (actual)

Study arms

  • Experimental
    Pioglitazone 30 mg QD + Metformin 1000 mg QD

    Drug: Pioglitazone and metformin

  • Active comparator
    Metformin 1000 mg QD

    Drug: Metformin

Interventions

  • DrugPioglitazone and metformin

    Drug pages: Pioglitazone · Metformin

    Pioglitazone 30 mg, tablets, orally, once daily and metformin 1000 mg, tablets, orally once daily for up to 16 weeks.

    Also known as: Actos, AD-4833XT, Fortamet

  • Pioglitazone placebo-matching tablets, orally, once daily and metformin 1000 mg, tablets, orally once daily for up to 16 weeks.

    Also known as: Fortamet

07

What researchers measure

Primary outcomes

  1. Change from randomization in Glycosylated Hemoglobin

    Time frame: Final Visit

Secondary outcomes

  1. Change from randomization in Fasting Plasma Glucose

    Time frame: Final Visit

  2. Change from randomization in Insulin

    Time frame: Final Visit

  3. Change from randomization in Pro-Insulin

    Time frame: Final Visit

  4. Change from randomization in Homeostasis Model Assessment

    Time frame: Final Visit

  5. Change from randomization in Triglycerides

    Time frame: Final Visit

  6. Change from randomization in Total Cholesterol

    Time frame: Final Visit

  7. Change from randomization in Low-Density Lipoprotein Cholesterol

    Time frame: Final Visit

  8. Change from randomization in high-density Lipoprotein Cholesterol

    Time frame: Final Visit

  9. Change from randomization in Lipid Fractionation

    Time frame: Final Visit

  10. Change from randomization in High Sensitivity C-Reactive Protein

    Time frame: Final Visit

  11. Change from randomization in Creatine Phosphokinase

    Time frame: Final Visit

08

Study locations

No study locations are listed for this record.

09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2005, a primary completion of Oct 2006 and a completion of Oct 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2008
First posted
Sep 18, 2008
Start
Jul 2005
Primary completionActual
Oct 2006
CompletionActual
Oct 2006
Last update
Jul 5, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 5, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00754403
Lead sponsor
Takeda
First posted
Sep 18, 2008
Start date
Jul 2005
Primary completion
Oct 2006
Completion
Oct 2006
Last update
Jul 5, 2010

Study contacts

VP Clinical Science Strategy
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pioglitazone · Metformin

Start the discussion